# Size of sepsis in Wales

<b>Recruitment status</b> No longer recruiting	<ul><li>Prospectively registered</li><li>Protocol</li></ul>		
Completed	[X] Results		
Condition category	[] Individual participant data		
	No longer recruiting  Overall study status  Completed		

## Plain English summary of protocol

Background and study aims

Sepsis is a potentially life-threatening condition, in which the body's immune system goes into overdrive in response to an infection, causing widespread inflammation (swelling). Severe sepsis is the name used when the sepsis causes one or more of the body's systems, such as the heart, liver or kidneys, to stop working properly (organ failure). In order to prevent this, it is vital that sepsis is recognized and treated quickly, with appropriate escalation to critical care (emergency care) if required. It has also been found that a patient with sepsis is five times more likely to die than a patient who has suffered a heart attack or stroke. In the UK, sepsis is estimated to be responsible for about 37,000 deaths every year at a cost of £2.5 billion, which in Wales this could equate to a figure of 1,800 deaths and a cost of £125 million. Currently however, accurate data collection in the non-critical care setting is still under development in Wales and it is thought that the real number will be far higher. Sepsis is a major cause of avoidable deaths and it is essential that to understand the size of the problem within Wales so that the quality of care that patients receive can be improved. The aim of this study is to look at the prevalence (commonness) of sepsis across acute hospitals (hospitals with an emergency department) across Wales.

## Who can participate?

Adults with suspected sepsis who have been admitted to an emergency department or critical care unit at participating hospitals in Wales.

# What does the study involve?

Over a 24 hour period, study staff will monitor the number of adults who are admitted to one of the participating acute hospitals with suspected sepsis. The patients who have sepsis confirmed are asked to complete a questionnaire to measure their quality of life 6 years after they are discharged from hospital. Ninety days after the start of the study, all participants have their medical notes reviewed by the study team in order to find out the number of deaths.

What are the possible benefits and risks of participating? There are no direct benefits or risks to participants taking part in this study.

Where is the study run from? Thirteen acute hospitals in Wales (UK) When is the study starting and how long is it expected to run for? June 2015 to February 2016

Who is funding the study?

- 1. Welsh Intensive Care Society (UK)
- 2. UK Sepsis Trust (UK)
- 3. Cwm Taf University Health Board (UK)

Who is the main contact? Dr Tamas Szakmany

# Contact information

## Type(s)

Scientific

#### Contact name

Dr Tamas Szakmany

#### **ORCID ID**

http://orcid.org/0000-0003-3632-8844

#### Contact details

Department of Anaesthesia Intensive Care and Pain Medicine Cardiff University Cardiff United Kingdom CF14 4XN

# Additional identifiers

EudraCT/CTIS number

**IRAS** number

ClinicalTrials.gov number

Secondary identifying numbers

3.1

# Study information

#### Scientific Title

The size of sepsis in Wales: Point prevalence study of sepsis in the acute hospital

# **Study objectives**

The aim of this study is to evaluate the prevalence of sepsis in acute hospitals in Wales.

Developing the digital data collection platform: http://www.ncbi.nlm.nih.gov/pubmed/27094989

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

NRES Committee West Midlands - Solihull, 07/04/2015, ref: 15/WM/0095

## Study design

Prospective observational multi-centre cohort study

## Primary study design

Observational

## Secondary study design

Cohort study

#### Study setting(s)

Hospital

## Study type(s)

Screening

## Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet.

# Health condition(s) or problem(s) studied

Sepsis

#### **Interventions**

The study will test the prevalence of sepsis on the general wards and Emergency Departments over a 24 hour period. Data will be collected using an electronic data collection tool on basic demographics, whether patients fulfil sepsis criteria according to the 2012 Consensus Conference definitions and whether Sepsis 6 has been delivered to the patients. Those patients who are screened positive for sepsis will be invited to fill out a validated health-related quality of life questionnaire (SF-36) 6 months following hospital discharge.

## Intervention Type

## Primary outcome measure

- 1. Prevalence of sepsis in the acute hospital setting is determined by reviewing patient notes on the study day (24 hours)
- 2. Mortality rate of sepsis is measured by reviewing patient notes at 90 days

#### Secondary outcome measures

- 1. Quality of life of sepsis survivors is determined using SF-36 questionnaire at 6 months
- 2. Completion and barriers of Sepsis 6 are determined by reviewing patient notes on the study day (24 hours)

## Overall study start date

17/06/2015

# Completion date

28/02/2016

# **Eligibility**

#### Key inclusion criteria

- 1. Must be admitted or transferred to either the ED or hospital ward or critical care area
- 2. NEWS score of 3 or above
- 3. High clinical suspicion of an infection
- 4. Have sepsis as defined by an infection together with two or more SIRS criteria
- 5. Aged 18 years or over

# Participant type(s)

**Patient** 

## Age group

Adult

## Lower age limit

18 Years

#### Sex

Both

# Target number of participants

200

#### Key exclusion criteria

Aged less than 18 years

#### Date of first enrolment

17/06/2015

#### Date of final enrolment

18/06/2015

# Locations

#### Countries of recruitment

**United Kingdom** 

Wales

# Study participating centre Glangwili General Hospital

Dolgwili Road

Carmarthen United Kingdom SA31 2AF

# Study participating centre Morriston Hospital

Heol Maes Eglwys Morriston Swansea United Kingdom SA6 6NL

# Study participating centre Nevill Hall Hospital

Brecon Road Abergavenny United Kingdom NP7 7EGA

# Study participating centre Prince Charles Hospital

Gurnos Road Merthyr Tydfil United Kingdom CF47 9DT

# Study participating centre Prince Philip Hospital

Bryngwyn Mawr Dafen Road Llanelli United Kingdom SA14 8QF

# Study participating centre Princess of Wales Hospital

Coity Road Bridgend United Kingdom CF31 1RQ

# Study participating centre Royal Glamorgan Hospital

Ynysmaerdy Pntyclun United Kingdom CF72 8XR

# Study participating centre Royal Gwent Hospital

Cardiff Road Newport United Kingdom NP20 2UB

# Study participating centre Singleton Hospital

Sketty Lane Sketty Swansea United Kingdom SA2 8QA

# Study participating centre Withybush Hospital

Fishguard Road Haverfordwest United Kingdom SA61 2PZ

# Study participating centre Wrexham Maelor Hospital

Croesnewydd Road Wrexham United Kingdom LL13 7TD

# Study participating centre Ysbyty Gwynedd

Penrhosgarnedd Bangor

## United Kingdom LL57 2PW

# Study participating centre Ysbyty Glan Clwydd

Rhuddlan Road Bodelwyddan Rhyl United Kingdom LL18 5UJ

# Sponsor information

## Organisation

Cwm Taf University Health Board

## Sponsor details

Ynysmeurig House Navigation Park Abercynon Wales United Kingdom CF45 4SN

## Sponsor type

Hospital/treatment centre

#### **ROR**

https://ror.org/00rh52j13

# Funder(s)

# Funder type

Charity

#### Funder Name

Welsh Intensive Care Society

#### Funder Name

**UK Sepsis Trust** 

#### Funder Name

Cwm Taf University Health Board

# **Results and Publications**

# Publication and dissemination plan

National and international conferences and publications.

# Intention to publish date

31/12/2016

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not expected to be made available

# **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/11/2015		Yes	No
Results article	results	01/11/2016		Yes	No
Results article	results	01/12/2016		Yes	No
HRA research summary			28/06/2023	No	No